IPACK Versus Popliteal Sciatic Nerve Block in ACL Reconstruction

Sujana Dontukurthy

Status and phase: Terminated; Phase 3

Conditions: Anterior Cruciate Ligament Tear

Treatments: Drug: Ropivacaine injection

Study type: Interventional

Funder types: Other

Identifiers

NCT03983941

STUDY00000281

Details and patient eligibility

About

This is a prospective study comparing femoral nerve block plus sciatic nerve block to femoral nerve block plus infiltration of the posterior knee capsule (IPACK) in patients undergoing arthroscopic anterior cruciate ligament reconstruction. Femoral nerve block via the adductor canal (FNB-AC) with IPACK may provide effective analgesia while avoiding the motor block involved with sciatic nerve block. The lack of motor block is important to facilitate postoperative ambulation and physical therapy.

Enrollment: 7 patients

Sex: All

Ages: Under 21 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients less than 21 years of age
• American Society of Anesthesiologists physical status I and II
• Undergoing elective anterior cruciate ligament reconstruction

Exclusion criteria

• They are unable or unwilling to take part in the study
• History of allergy to any of the medications administered for the nerve block
• Contraindication to peripheral nerve block
• Patients who are unable to understand instructions or questions related to the study or the families required language interpretation
• Patients who consume opioid medications for more than three days per week for more than a month prior to surgery

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

7 participants in 2 patient groups

FNB-AC + Sciatic nerve block

Active Comparator group

Description:

Patients will receive up to 20 mL of 0.2% ropivacaine for FNB-AC and up to 20 mL of 0.2% ropivacaine for sciatic nerve block under ultrasound guidance.

Treatment:

Drug: Ropivacaine injection

FNB-AC + IPACK

Experimental group

Description:

Patients will receive up to 20 mL of 0.2% ropivacaine for FNB-AC and up to 20 mL of 0.2% ropivacaine for posterior knee capsular infiltration under ultrasound guidance (IPACK)

Treatment:

Drug: Ropivacaine injection